ストックスクリーナーアプリを入手
32.88
0.12%
-0.04
前日終値:
$32.92
開ける：
$32.66
24時間の取引高:
452.69K
Relative Volume:
0.55
時価総額：
$2.14B
収益：
$10.00M
当期純損益:
$-425.15M
株価収益率:
-3.6146
EPS:
-9.0964
ネットキャッシュフロー:
$-210.48M
1週間 パフォーマンス:
+5.15%
1か月 パフォーマンス:
+4.65%
6か月 パフォーマンス:
+27.34%
1年 パフォーマンス:
+93.64%
1日の値動き範囲:
$32.38
$33.29
1週間の範囲:
$29.88
$33.66
52週間の値動き範囲:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
32.88 | 2.06B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan
Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan
Zenas BioPharma (ZBIO) Institutional Ownership 2026 - MarketBeat
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan
HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat
SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - Vinanet
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com
Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative
Zenas BioPharma (ZBIO) Slides 3.55% to $31.29 as Biotech Sentiment Turns CautiousTotal Put Call - dars.gov.et
Zenas BioPharma (ZBIO) Edges Higher to $32.44 as Biotech Momentum BuildsMA Cross Alert - Vinanet
Zenas BioPharma (ZBIO) Rises 1.41% to $32.44 as Shares Hold Above Key SupportSynthetic Long - vinanet.vn
Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review
Zenas BioPharma, Inc. (ZBIO): Investor Outlook On A Potential 35% Upside - DirectorsTalk Interviews
Zenas BioPharma (ZBIO) Holds Firm at $32.43 as Biotech Sentiment SteadiesBreakout Trade - vinanet.vn
Zenas BioPharma (ZBIO) Edges Up 0.97% as Shares Hold Between Support and ResistanceCash Flow Strong Stocks - Vinanet
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, In - The National Law Review
Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Levi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025 - The National Law Review
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas Biopharma Inc (ZBIO) Balance Sheet - TradingKey
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zenas Biopharma Inc (ZBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% HigherStill a Buy? - MarketBeat
ZBIO|Zenas Biopharma Inc|Price:30.390|Chg%:-0.600 - TradingKey
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Zenas Biopharma Inc (ZBIO) 財務データ
収益
当期純利益
現金流量
EPS
Zenas Biopharma Inc (ZBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
May 18 '26 |
Buy |
16.88 |
60,000 |
1,012,800 |
96,928 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 29 '26 |
Buy |
17.62 |
35,000 |
616,700 |
1,786,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):